Corium International (CORI) and Its Competitors Head to Head Review

Corium International (NASDAQ: CORI) is one of 104 public companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Corium International to similar businesses based on the strength of its valuation, risk, analyst recommendations, dividends, profitability, earnings and institutional ownership.

Insider and Institutional Ownership

89.1% of Corium International shares are owned by institutional investors. Comparatively, 44.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 45.7% of Corium International shares are owned by company insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Corium International has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Corium International’s competitors have a beta of 37.68, suggesting that their average stock price is 3,668% more volatile than the S&P 500.

Earnings and Valuation

This table compares Corium International and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Corium International $31.86 million -$47.79 million -6.69
Corium International Competitors $8.31 billion $1.11 billion 159.06

Corium International’s competitors have higher revenue and earnings than Corium International. Corium International is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


This table compares Corium International and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Corium International -149.99% -482.64% -62.37%
Corium International Competitors -2,433.13% -68.53% -8.70%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Corium International and its competitors, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corium International 0 0 6 0 3.00
Corium International Competitors 904 3898 6888 183 2.53

Corium International presently has a consensus price target of $13.00, indicating a potential upside of 16.38%. As a group, “Pharmaceuticals” companies have a potential upside of 19.18%. Given Corium International’s competitors higher probable upside, analysts clearly believe Corium International has less favorable growth aspects than its competitors.


Corium International competitors beat Corium International on 8 of the 13 factors compared.

Corium International Company Profile

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with's FREE daily email newsletter.

Leave a Reply